Drug Profile
Research programme: ovarian cancer immunotherapeutics - HRA Pharma/Pantarhei Bioscience
Alternative Names: Zona pellucida antigens - HRA Pharma/Pantarhei Bioscience; ZPLatest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator Pantarhei Bioscience
- Developer HRA Pharma; Imperial College of Science, Technology and Medicine; Pantarhei Bioscience; University of Turku
- Class Antigens; Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 06 Apr 2023 Preclinical development is ongoing in Ovarian cancer in United Kingdom, Finland, France, Netherlands (unspecified route) (Pantarhei Bioscience pipeline, April 2023)
- 02 May 2022 HRA Pharma has been acquired by Perrigo
- 28 Nov 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in France